A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC

被引：0
|
作者：
Mok, T. S. K. [1 ]
Jotte, R. M. [2 ]
Cappuzzo, F. [3 ]
Reck, M. [4 ]
Papadimitrakopoulou, V. [5 ]
West, H. J. [6 ]
Sandler, A. [7 ]
Mocci, S. [7 ]
Coleman, S. [7 ]
Asakawa, T. [8 ]
Socinski, M. A. [9 ]
机构：
[1] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Rocky Mt Canc Ctr USA Oncol Network, Denver, CO USA
[3] Osped Civile, Ist Toscano Tumori, UO Oncol Med, Livorno, Italy
[4] ARCN, German Ctr Lung Res DZL, Lung Clin Grosshansdorf, Grosshansdorf, Germany
[5] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[6] Swedish Canc Inst, Seattle, WA USA
[7] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[8] Genentech Inc, Biostat, San Francisco, CA 94080 USA
[9] Florida Hosp, Inst Canc, Orlando, FL USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
483TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1-selected chemotherapy (chemo)-naive NSCLC patients (pts)
    De Marinis, F.
    Jassem, J.
    Spigel, D. R.
    Lam, S.
    Mocci, S.
    Sandler, A.
    Lopez-Chavez, A.
    Deng, Y.
    Giaccone, G.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] IMpower132: A phase III clinical program-1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
    West, Howard Jack
    Nishio, Makoto
    Dols, Manuel Cobo
    Saito, Haruhiro
    Howland, Michael
    Hoang, Tien
    Asakawa, Takashi
    Sandler, Alan
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) plus chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC
    Reck, M.
    Wehler, T.
    Orlandi, F.
    Nogami, N.
    Barone, C.
    Moro-Sibilot, D.
    Shtivelband, M.
    Gonzalez Larriba, J. L.
    Rothenstein, J.
    Frueh, M.
    Shankar, G.
    Lee, A.
    Deng, Y.
    Patel, H.
    Kelsch, C.
    Lin, W.
    Socinski, M. A.
    ANNALS OF ONCOLOGY, 2018, 29 : 498 - 499
  • [4] Phase III study of atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with treatment-naive advanced, recurrent or metastatic NSCLC unsuitable for platinum (plat)-based chemo
    Lee, S. M.
    Schulz, C.
    Cardona, A.
    Bartakova, P.
    Peters, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) plus chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).
    Reck, Martin
    Karagiannis, Tom
    Wehler, Thomas
    Shtivelband, Mikhail
    Gonzalez-Larriba, Jose-Luis
    Rothenstein, Jeffrey
    Frueh, Martin
    Deng, Yu
    Lopez-Chavez, Ariel
    Sandler, Alan
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) plus chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.
    Socinski, Mark A.
    Jotte, Robert M.
    Cappuzzo, Federico
    Orlandi, Francisco Jorquera
    Stroyakovskiy, Daniil
    Nogami, Naoyuki
    Rodriguez-Abreu, Delvys
    Moro-Sibilot, Denis
    Thomas, Christian A.
    Barlesi, Fabrice
    Finley, Gene Grant
    Kelsch, Claudia
    Lee, Anthony
    Coleman, Shelley
    Shen, Yijing
    Kowanetz, Marcin
    Lopez-Chavez, Ariel
    Sandler, Alan
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups
    Kowanetz, Marcin
    Socinski, Mark A.
    Zou, Wei
    McCleland, Mark
    Yang, Nancy
    Chavez, Ariel Lopez
    Spira, Alexander
    Mazieres, Julien
    Braiteh, Fadi
    Shames, David
    Sandler, Alan
    Reck, Martin
    CANCER RESEARCH, 2018, 78 (13)
  • [8] IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups
    Reck, M.
    Kowanetz, M.
    Socinski, M. A.
    Zou, W.
    McCleland, M.
    Yang, N.
    Chavez, Lopez A.
    Spira, A.
    Mazieres, J.
    Braiteh, F.
    Shames, D.
    Sandler, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 239 - 239
  • [9] First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Jotte, Robert M.
    Socinski, Mark A.
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    West, Howard J.
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Cappuzzo, Federico
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S302 - S303
  • [10] First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Cappuzzo, Frederico
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    Jotte, Robert
    West, Howard
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Socinski, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1296 - S1297
12345